Firstly, to determine whether TPL2 overexpression is sufficient to promote ADI prostate cancer growth, we established AD-LNCaP stable cell lines overexpressing either N-terminally myc-tagged wild-type [myc-TPL2 (WT)], a constitutively activated form with a deletion of 70 amino acids in its C-terminus [myc-TPL2 (ΔC)], or a kinase-inactive form of TPL2 [myc-TPL2 (D270A)] using the pBabe-puro vector (Figure 2A). The gene discussed is MAP3K8; the disease is Familial prostate cancer.